St John McGrath
Président chez Bioshin Ltd.
Postes actifs de St John McGrath
Sociétés | Poste | Début | Fin |
---|---|---|---|
Artizan Biosciences, Inc.
Artizan Biosciences, Inc. Medical/Nursing ServicesHealth Services Artizan Biosciences, Inc. engages in the provision of healthcare services. It develops curative treatments for inflammatory diseases. The company was founded by Richard A. Flavell, Noah W. Palm and Marcel R. de Zoete and is headquartered in New Haven, CT. | Directeur/Membre du Conseil | - | - |
Bioshin Ltd.
Bioshin Ltd. BiotechnologyHealth Technology Part of Biohaven Ltd., BioShin Ltd. is a biopharmaceutical company based in Shanghai, China. The Chinese company is advancing the Biohaven clinical portfolio in the Asia-Pacific region, excluding Japan and South Korea. BioShin is focused on discovering, developing, and commercializing novel treatments for patients with neuro-immune diseases in China and the Asia-Pacific region. The company has a proven and established late-stage portfolio from its strategic partner, Biohaven Pharmaceuticals Inc. in the US, and is poised to quickly launch novel medicines for patients in need. The CEO of the company is Karl Lintel. | Président | - | - |
President | - | - | |
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | Private Equity Investor | 01/01/2023 | - |
Historique de carrière de St John McGrath
Anciens postes connus de St John McGrath
Sociétés | Poste | Début | Fin |
---|---|---|---|
BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | Corporate Officer/Principal | 21/06/2017 | 01/12/2022 |
Bristol-Myers Squibb Pharmaceutical Research Institute | Corporate Officer/Principal | 01/01/2013 | 01/01/2017 |
BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/05/2005 | 01/04/2008 |
Tufts University School of Medicine | Corporate Officer/Principal | 01/07/1995 | 01/04/2005 |
Formation de St John McGrath
University College Dublin | Undergraduate Degree |
Royal College of Surgeons | Doctorate Degree |
Harvard T.H. Chan School of Public Health | Doctorate Degree |
Statistiques
Internationale
Etats-Unis | 8 |
Irlande | 3 |
Chine | 2 |
Opérationnelle
Corporate Officer/Principal | 4 |
Doctorate Degree | 2 |
Undergraduate Degree | 1 |
Sectorielle
Consumer Services | 5 |
Health Technology | 4 |
Health Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
Entreprise privées | 5 |
---|---|
Biohaven Pharmaceutical Holding Co. Ltd.
Biohaven Pharmaceutical Holding Co. Ltd. Pharmaceuticals: MajorHealth Technology Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT. | Health Technology |
Bristol-Myers Squibb Pharmaceutical Research Institute | |
Artizan Biosciences, Inc.
Artizan Biosciences, Inc. Medical/Nursing ServicesHealth Services Artizan Biosciences, Inc. engages in the provision of healthcare services. It develops curative treatments for inflammatory diseases. The company was founded by Richard A. Flavell, Noah W. Palm and Marcel R. de Zoete and is headquartered in New Haven, CT. | Health Services |
Bioshin Ltd.
Bioshin Ltd. BiotechnologyHealth Technology Part of Biohaven Ltd., BioShin Ltd. is a biopharmaceutical company based in Shanghai, China. The Chinese company is advancing the Biohaven clinical portfolio in the Asia-Pacific region, excluding Japan and South Korea. BioShin is focused on discovering, developing, and commercializing novel treatments for patients with neuro-immune diseases in China and the Asia-Pacific region. The company has a proven and established late-stage portfolio from its strategic partner, Biohaven Pharmaceuticals Inc. in the US, and is poised to quickly launch novel medicines for patients in need. The CEO of the company is Karl Lintel. | Health Technology |
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | Finance |
- Bourse
- Insiders
- St John McGrath
- Expérience